Galactose-mediated oridonin albumin nanoparticle and preparation method thereof

Abstract

The invention discloses a galactose-mediated oridonin albumin nanoparticle, which is prepared from the raw material and auxiliary materials, wherein the raw material is oridonin; the auxiliary materials consist of galactosylation albumin, crosslinking agent, cryoprotectant and water; the mass ratio of the use amount of the raw material and the auxiliary materials is as follows: by 10ml of nanoparticle preparation, the oridonin is 2.0-40.0mg, the galactosylation albumin is 50.0-400.0mg, the crosslinking agent is 0.4-8.4mg, the cryoprotectant is 0 or 0.1-0.5g, and the balance is water. The galactose-mediated oridonin albumin nanoparticle disclosed by the invention has a good biocompatibility. After the galactose-mediated oridonin albumin nanoparticle is made into injection-purpose nanometer solution, the bioavailability of the medicine is favorably increased, the medicine administration dose is reduced, the toxic and side effect is lowered, and the purpose on changing the in-vivo distribution of the medicine, prolonging the medicine acting time and improving the bioavailability can be achieved. The preparation method is simple and easy to realize and is suitable for large-scale production.

Description

Technical field [0001] The invention relates to a galactose-mediated oridonin albumin nanoparticle and a preparation method thereof. Background technique [0002] Liver cancer is one of the most common malignant tumors in the world, and its incidence and mortality are on the rise. According to statistics, there are approximately 6.35 million new malignant tumors each year, of which 300,000 are primary liver cancer, accounting for 4.7%. Both mainland China and Taiwan are areas with a high incidence of liver cancer. The annual incidence of liver cancer exceeds 130,000, accounting for 43.7% of the world's annual deaths from liver cancer. Therefore, it has become more urgent to find efficient methods to treat liver cancer. The current clinical treatments are generally surgery, radiotherapy, and chemotherapy. However, due to the insidious onset, high degree of malignancy, and rapid development of liver cancer, patients are often not aware of the disease at the early stage of illness...

AI Technical Summary

Problems solved by technology

In the absence of related reports in the prior art, a kind of Oridonium fruticosa has been developed with the advantages of good curative effect, good biocompatibility, high bioavailability, stable system, suitable for large-scale industrial production, and low cost. The albumin nanoparticle mediated by galactose and its preparation method are very difficult, requiring creative work, a large number of experiments and condition screening

Images